Cardiome Oxyprim, Chronic Gout Drug Trials May Use Surrogate Endpoints For Approval, Cmte. Says

Surrogate endpoint should seek a reduction in serum uric acid to a level of 6 mg/dL. Clinical outcome trials to confirm benefits of chronic gout products through reduction in gouty attacks should be carried out post-approval.